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A 29-year-old woman with stage IVB Hodgkin’s lymphoma was treated with doxorubicin,
bleomycin, vinblastine, and dacarbazine. Two weeks after the ﬁrst cycle was completed, she
developed pruritic, linear erythematous lesions in a ﬂagellate-like pattern on the trunk, neck
and arms. After oral prednisone therapy and cessation of bleomycin, the lesions started to
recede.
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leomycin is a cytotoxic glycopeptide, isolated from the soil
ungus Streptomyces verticillus. It inhibits the incorporation of
hymidine, causing DNA fragmentation. Bleomycin is used to
reat severalmalign tumors such asHodgkin’s lymphoma (HL),
quamous cell carcinoma and germ cell tumors.1
The side effects of this drug are gastrointestinal (mucosi-
is, anorexia, and weight loss), respiratory (tachypnea,
neumonitis and pulmonary ﬁbrosis), and dermatological
erythema, cutaneous rash, vesicles, palmary and plantar
caling, hyperpigmentation, alopecia and the less common
agellate dermatitis) as well as general symptoms such as
ever and malaise.2
Here we report on a case of a 29-year-old female patient
ith HL, who developed the cutaneous reaction known as
leomycin-induced ﬂagellate dermatitis during treatment.
Case report
The 29-year-old, female patient (ETL) was diagnosed in March
2012 with HL (nodular sclerosis subtype, stage IIIB-X with all B
symptoms: involvement of cervical, retroperitoneal, and sup-
raclavicular lymph nodes; bulky mass>10 cm). International
prognostic score (IPS) was 1 (albumin<4g/dL). HIV, hepatitis
B and hepatitis C serologies were negative. The doxorubicin
(25mg/m2), bleomycin (10mg/m2), vinblastine (6mg/m2), and
dacarbazine (375mg/m2) chemotherapy protocol (ABVD) was
the regimen of choice followed by involved-ﬁeld radiotherapy
(IF-RT) of the bulky mass.
Nearly two weeks after the ﬁrst cycle of ABVD, just before
the second cycle, the patient started with generalized and
increasing pruritus along with the appearance of several
linearly arranged hyperchromic plaques in the cervical region,
trunk and arms. There was a moderate response to the∗ Corresponding author.
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Figure 2 – Skin biopsy revealing an inﬂammatory dermal298 rev bras hematol hem
pruritus with the administration of prednisone (20mg/day),
although established lesions remained intact.
The investigation went further and a skin biopsy was
performed revealing an inﬂammatory dermal inﬁltration sug-
gesting a drug eruption compatible with bleomycin-induced
ﬂagellate dermatitis. Due to the continuation of the skin
lesions with severe pruritus, bleomycin was withdrawn from
the regimen on Day 1 of Cycle 4.
The patient continued to be treated with the AVD regimen
up to the sixth cycle and still received prednisone (20mg/day),
which was gradually reduced until suspension in September
2012 (one month after completing the sixth cycle). After the
suspension of bleomycin, the skin lesions gradually subsided
with complete resolution after three months. The patient was
referred for IF-RT and currently has an optimal clinical state,
without any evidence of lymphoma.
Discussion
Herein, we report on a case of bleomycin-induced ﬂagel-
late dermatitis in a 29-year-old woman with HL after the
introduction of the ABVD chemotherapy protocol. Although
doxorubicin, vinblastine, and dacarbazine can cause erythe-
matous or even necrotic skin lesions, the whip-like pattern
associated with hyperpigmentation and severe pruritus is
characteristic of bleomycin-induced ﬂagellate dermatitis.
Thus, a diagnosis of bleomycin-induced dermatitis is the
most likely one. The term ‘ﬂagellate’ derives from the Latin
‘ﬂagellum’ referring to the characteristic whip-like appear-
ance of the eruption. It occurs in 10% of patients treated
with this drug,4 although severe and disseminated lesions
are very rare. The typical skin alterations are pruritic, multi-
ple linear lesions, initially urticarial and later with changes
in pigmentation, located mainly on the thorax and back
(Figure 1).3,4
First, it was believed that the occurrence of bleomycin-
induced ﬂagellate dermatitis was dose-related, but some
patients developed this condition after receiving very low
doses of bleomycin. The time between the administration and
the onset of the clinical symptoms varies between one day and
nine weeks.3After administration, a hydrolase enzyme metabolizes
bleomycin. This enzyme is almost not found in skin and lung
tissues which may explain the accumulation and consequent
Figure 1 – Flagellate dermatitis in upper back, with
hyperchromia and a “whip-like” pattern.inﬁltration (arrow) suggesting drug eruption.
aggression in these areas. Another pathological mechanism
proposed to explain these lesions suggests that even minor
trauma to the skin, for example a scratch or pressure against
bone prominences, may cause increased blood ﬂow to these
areas allowing the drug to accumulate.5
There are no histopathological ﬁndings that absolutely
characterize bleomycin-induced ﬂagellate dermatitis. In this
case report, the skin biopsy revealed inﬂammatory dermal
inﬁltration with eosinophil predominance consistent with
several other drug eruptions (Figure 2), therefore correla-
tion with clinical ﬁndings is needed. The ﬁndings in the
acute phase include vacuolization in the basal layers of the
epidermis, melanin incontinence, and scattered dyskeratotic
keratinocytes. In later stages, merely a few post-inﬂammatory
changes can be found. Histological and ultra-structural stud-
ies suggest that bleomycin reduces the epidermal turnover,
resulting in prolonged contact between melanocytes and
keratinocytes.3,6
The decision to withdraw the drug from therapy seems
to be consensus in the literature among different authors,
however, the management of the symptoms varies in accor-
dance with the experience of each service. Generally, therapy
with corticosteroids or antihistamines has been beneﬁcial,
decreasing pruritus and limiting trauma to the skin.4,6 The
eruptions are usually self-limiting and recede after 6–8
months yet they can reoccur or worsen after further exposure
to bleomycin.3,6 In this case report, the eruptions lasted for
approximately ﬁve months.
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